IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 35.456
AS - Asia 3.599
NA - Nord America 2.130
SA - Sud America 298
AF - Africa 73
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 41.562
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 34.844
US - Stati Uniti d'America 2.015
SG - Singapore 1.526
CN - Cina 944
VN - Vietnam 596
FR - Francia 291
BR - Brasile 192
BD - Bangladesh 182
HK - Hong Kong 113
FI - Finlandia 109
DE - Germania 56
AR - Argentina 51
MX - Messico 44
GB - Regno Unito 43
CA - Canada 42
JP - Giappone 39
IQ - Iraq 32
ID - Indonesia 23
IN - India 22
ZA - Sudafrica 19
CH - Svizzera 18
EC - Ecuador 18
PH - Filippine 17
IE - Irlanda 14
VE - Venezuela 13
NL - Olanda 12
TH - Thailandia 12
TR - Turchia 12
RU - Federazione Russa 11
SA - Arabia Saudita 11
DZ - Algeria 10
JM - Giamaica 10
CL - Cile 9
CO - Colombia 9
ES - Italia 9
PK - Pakistan 9
NP - Nepal 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
KE - Kenya 7
MA - Marocco 7
TW - Taiwan 7
MY - Malesia 6
TN - Tunisia 6
UA - Ucraina 6
LB - Libano 5
PL - Polonia 5
BY - Bielorussia 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
RO - Romania 4
SE - Svezia 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
AU - Australia 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
MU - Mauritius 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
EG - Egitto 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
KR - Corea 2
LT - Lituania 2
MM - Myanmar 2
OM - Oman 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BZ - Belize 1
CD - Congo 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
GT - Guatemala 1
IL - Israele 1
IR - Iran 1
KW - Kuwait 1
LC - Santa Lucia 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MQ - Martinica 1
NE - Niger 1
NI - Nicaragua 1
PA - Panama 1
Totale 41.552
Salva come PNG Salva come JPEG
Città #
Genova 21.519
Genoa 8.338
Rapallo 2.417
Vado Ligure 2.268
San Jose 748
Singapore 705
Lauterbourg 272
Ashburn 179
Ho Chi Minh City 168
Beijing 140
Hanoi 140
New York 128
Hong Kong 111
Council Bluffs 110
Helsinki 95
Santa Clara 75
Frankfurt am Main 45
Bordighera 39
Tokyo 37
Haiphong 32
Los Angeles 31
Milan 30
Boardman 26
Mexico City 25
Rome 25
Da Nang 24
Orem 22
Chicago 21
São Paulo 21
Tianjin 18
Dallas 17
Turin 17
Buffalo 16
Zurich 16
Lappeenranta 13
Atlanta 12
Cardiff 12
Dublin 12
Guangzhou 11
London 11
Bologna 10
Can Tho 10
Baghdad 9
Biên Hòa 9
Hải Dương 9
Montreal 8
Naples 8
Shanghai 8
Toronto 8
Agawam 7
Amman 7
Amsterdam 7
Buenos Aires 7
City of London 7
Des Moines 7
Guayaquil 7
Houston 7
Johannesburg 7
Kingston 7
Nairobi 7
Phoenix 7
Quận Ba 7
San Francisco 7
Thái Bình 7
Jeddah 6
Maple Grove 6
Ninh Bình 6
Nuremberg 6
Palermo 6
Philadelphia 6
Warsaw 6
Bắc Ninh 5
Cape Town 5
Denver 5
Dhaka 5
Erbil 5
Hangzhou 5
Huntington 5
Memphis 5
Miami 5
Modena 5
Quito 5
Reggio Emilia 5
Seattle 5
The Bronx 5
Bangkok 4
Bari 4
Brescia 4
Charlotte 4
Chennai 4
Curitiba 4
Florence 4
Karbala 4
Newark 4
Orangeburg 4
Phủ Lý 4
Piscataway 4
Shenzhen 4
Sumaré 4
Thái Nguyên 4
Totale 38.302
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 316
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 236
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 233
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care 226
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 221
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 220
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 220
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 216
Acromegaly is associated with increased cancer risk: A survey in Italy 216
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 212
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 212
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 210
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 210
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 207
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 205
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 204
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 202
Pituitary image: pituicytoma. 201
Computed tomography colonography in acromegaly 200
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 191
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 190
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 190
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 189
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 188
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 187
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 187
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 186
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 184
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 184
"Present and future of immunotherapy in Neuroendocrine Tumors" 184
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 183
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 183
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 183
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 182
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 181
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 181
Hormone receptors analysis in idiopathic progressive subglottic stenosis 181
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 180
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 178
The pathology of the ulnar nerve in acromegaly. 177
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 177
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system 176
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 176
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 176
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 175
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 175
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 171
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 170
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 169
A pilot study on nerve ultrasound in acromegaly 169
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 169
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 166
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 165
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 163
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 161
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 161
Somatostatin receptor scintigraphy in thoracic diseases 160
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 160
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 160
On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic 159
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 159
Initial staging of lymphoma with octreotide and other receptor imaging agents. 159
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 159
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 159
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 158
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 158
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 157
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 157
Doe4s biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors? 156
Managing Cushing's disease: The state of the art 156
Rare diseases in clinical endocrinology: A taxonomic classification system 156
Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients 156
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 155
A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency 155
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 154
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 154
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 154
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 154
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 153
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 153
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 153
Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly 152
Dopamine receptor expression and function in corticotroph ectopic tumors. 151
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors 151
Somatostatin receptor ligands in the treatment of acromegaly 151
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 150
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 150
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 150
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 149
Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. 149
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 148
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 148
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 147
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 147
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 147
Trigger Finger, an Early Musculoskeletal Manifestation of Acromegaly 146
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. 146
Emerging drugs for the treatment of acromegaly 146
Sympathovagal imbalance in acromegalic patients 145
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 145
Totale 17.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.894
article - articoli 134.661
book - libri 0
conference - conferenze 661
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 572
Totale 271.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021168 0 0 0 0 0 0 0 0 0 0 0 168
2021/20223.426 98 221 283 437 90 251 257 736 174 317 163 399
2022/20232.958 329 208 39 270 442 524 23 219 531 26 302 45
2023/20241.652 90 221 39 186 131 283 108 69 100 66 100 259
2024/20255.496 153 423 155 368 781 573 564 784 247 267 502 679
2025/202610.122 1.078 332 1.010 921 1.120 1.032 1.611 419 774 889 650 286
Totale 42.176